GlaxoSmithKline first-time-in-man clinical trial

Reading Time: < 1 minute

GlaxoSmithKline (GSK), the pharmaceutical giant, is now recruiting for a clinical trial–often referred to as the NOGO trial. The drug being tested is called ‘GSK1223249’ which isn’t the catchiest of titles which is why it is often refereed to as the NOGO trial!

There are  three centres recruiting from the UK, which are based in Queen Elizabeth Hospital in Birmingham, Royal Free Hospital in London and Addenbrookes Hospital in Cambridge. This drug will be taken by an intravenous infusion at the centres in either one dose, or two doses separated by four weeks. Participants can only be involved with one part of the study and the drug will be tested against a ‘dummy drug’ called a placebo.  This trial will be testing for the safety of these doses (by conducting a number of tests during the trial period) and will not test for the drugs effectiveness.

It is therefore unlikely that people will derive any significant benefit from this trial. However, safety trials are a necessary step in moving the drug forward to a larger trial to test for its effectiveness.

To help GSK recruit for this trial and generally raise awareness of this opportunity, we have created an information sheet which provides more information on what the drug does, what’s involved and the contact details if you think you are eligible to take part.

*note added after posting*

This trial has now completed recruitment. Please see our ‘how to get involved with research’ section on our website for more opportunities to take part.

Leave a Reply

Your email address will not be published. Required fields are marked *